The selective sphingosine-1-phosphate receptor 1 (S1P1) ponesimod is superior to teriflunomide in the treatment of relapsing MS, according to the first RCT comparing two oral disease modifying treatments. A phase 3 study comprising 1,133 adult patients from 28 countries compared 20mg daily of the oral ponesimod with 14mg daily of oral teriflunomide over 108 weeks. ...
First phase 3 study compares two oral DMTs in RMS disease
By Mardi Chapman
30 Mar 2021